| Ms Lynn A Griffin, CNM | |
|
6002 Westgate Blvd Ste 230, Tacoma, WA 98406-2572 | |
| (253) 761-2244 | |
| (253) 761-1040 |
| Full Name | Ms Lynn A Griffin |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 6002 Westgate Blvd Ste 230, Tacoma, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336556422 | NPI | - | NPPES |
| 353535 | Other | WA | WA LABOR & INDUSTRIES |
| 2048505 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | AP60419029 (Washington) | Primary |
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.
The Washington Post: "The nation's governors are emerging as a formidable lobbying force as health-care reform moves through Congress and states overburdened by the recession brace for the daunting prospect of providing coverage to millions of low-income residents.
The U.S. Department of Health and Human Services (HHS) issued an interim final rule with request for comments today to strengthen its enforcement of the rules promulgated under the Health Insurance Portability and Accountability Act (HIPAA).
A new study to assess the effects of U.S.. Food and Drug Administration (FDA) regulations and guidance, intended to encourage greater inclusion of women and minorities in clinical drug trials, has shown appropriate levels of female participation based on the estimated sex ratio of people affected by a particular disease.
Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lynn A Griffin, CNM 6002 Westgate Blvd Ste 230, Tacoma, WA 98406-2572 Ph: (253) 761-2244 | Ms Lynn A Griffin, CNM 6002 Westgate Blvd Ste 230, Tacoma, WA 98406-2572 Ph: (253) 761-2244 |
News Archive
Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.
The Washington Post: "The nation's governors are emerging as a formidable lobbying force as health-care reform moves through Congress and states overburdened by the recession brace for the daunting prospect of providing coverage to millions of low-income residents.
The U.S. Department of Health and Human Services (HHS) issued an interim final rule with request for comments today to strengthen its enforcement of the rules promulgated under the Health Insurance Portability and Accountability Act (HIPAA).
A new study to assess the effects of U.S.. Food and Drug Administration (FDA) regulations and guidance, intended to encourage greater inclusion of women and minorities in clinical drug trials, has shown appropriate levels of female participation based on the estimated sex ratio of people affected by a particular disease.
Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.
› Verified 9 days ago
Alexandra Michel, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 9040 A Fitzsimmons, Madigan Army Medical Center - Ob Gyn, Tacoma, WA 98431 Phone: 253-968-1341 | |
Mrs. Ashley Sue Cummings, CNM, ARNP Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 2102 N Pearl St Ste 405, Tacoma, WA 98406 Phone: 253-752-8822 Fax: 253-752-5400 | |
Donna L Payne-snyder, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1812 S J St, Suite 120, Tacoma, WA 98405 Phone: 253-207-4890 Fax: 253-207-4871 | |
Mrs. Danielle Lee Molinar, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 210-875-0218 | |
Melissa Lesta West, ARNP MIDWIFE Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-2252 | |
Susan N. Hodgson, C.N.M. Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 209 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-596-3300 | |
Mrs. Judith Ann Michalk, ARNP, MPH. Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 813 Martin Lurther King Jr Way, Suite # 200, Tacoma, WA 98405 Phone: 253-770-3900 |